In AMD murine models, multiple rAAV overexpressing diverse anti-angiogenic therapeutic factors (anti-VEGF antibodies, anti-VEGF small hairpin RNA (shRNA), and others) are being used (as reviewed in [33,181] (https://clinicaltrials.gov/, accessed 23 July 2024). The gene discussed is VEGFA; the disease is age-related macular degeneration.